CD Biosynsis offers comprehensive CRISPR-based Gene Editing Services, leveraging the power and precision of the CRISPR/Cas system for applications ranging from high-throughput functional genomics screening to the creation of custom cell lines. Our platform supports the full spectrum of CRISPR applications, including CRISPR-Cas9 for precise Knockout and Knock-in modifications, and specialized services for Library Construction and rigorous Off-Target Screening. We provide researchers and pharmaceutical clients with the tools to accelerate target identification, validate drug candidates, and engineer superior therapeutic and bioproduction cell lines.
Get a QuoteThe CRISPR/Cas system is the most powerful tool for precise and efficient genetic manipulation. By combining a guide RNA (gRNA) with the Cas9 nuclease, CRISPR enables targeted modification of DNA sequences. Our services focus on maximizing on-target activity and minimizing off-target effects, ensuring that the genetic modifications are specific, stable, and functionally relevant. This capability is foundational for modern drug discovery, disease modeling, and synthetic biology applications.
Design and synthesis of high-complexity gRNA libraries (KO, activation, interference) for genome-wide screens.
Pooled libraries used to systematically identify genes essential for survival, drug resistance, or specific phenotypes.
Identifying novel drug targets, resistance mechanisms, and synthetic lethal interactions for therapeutic advancement.
Precise insertion of reporter genes, epitope tags, or regulatory elements for advanced disease modeling and assay development.
Deep sequencing and computational analysis to rigorously validate the specificity of gRNA sequences, ensuring clean genetic modifications.
Our systematic approach ensures high editing efficiency, clean results, and validated cell lines.
Design & Optimization
Delivery & Editing
Clonal Selection & Expansion
Validation & Screening
Target identification and gRNA sequence design (minimizing off-targets).
For Libraries: Design and synthesis of complex, high-titer lentiviral or AAV library vectors.
For Knock-in: Design of the ssDNA or plasmid Homology Directed Repair (HDR) donor template.
Efficient delivery of Cas9 and gRNA components into the target cell type (plasmid, RNP, or viral vector).
For Screening: Transduction of the pooled CRISPR library at low MOI (Multiplicity of Infection).
Optimization of transfection/transduction for maximum editing efficiency.
Validation: Sanger sequencing and ddPCR to confirm on-target edits in monoclonal lines.
Off-Target Screening: Deep sequencing to verify the absence of unintended edits.
Functional assays (e.g., Western Blot, qRT-PCR) to confirm protein or RNA level changes.
Minimized Off-Target Effects
Proprietary gRNA design algorithms and dedicated Off-Target Screening ensure the highest level of editing specificity.
Expertise in Knock-in & HDR
Specialized methods to boost the efficiency of Homology Directed Repair (HDR) for precise insertion of large DNA sequences.
Advanced Library Construction
Delivering high-titer, high-coverage CRISPR libraries for robust genome-wide functional screens across various cell types.
Rigorous Monoclonal Validation
All Knockout and Knock-in cell lines are validated clonally using sequencing and functional verification for guaranteed results.
"The CRISPR Knock-in service was flawless. We received a validated, monoclonal cell line with a fluorescent tag precisely inserted at the C-terminus of our target gene, saving us months of in-house optimization."
Dr. Alex Chu, Lead Molecular Biologist, Biopharma R&D
"CD Biosynsis provided a high-quality CRISPR Knockout Library that we used to screen for essential genes in cancer resistance. The clean, unbiased library complexity was key to the success of our functional genomics screen."
Prof. Sarah Klein, Director, Cancer Systems Biology Center
"Their rigorous Off-Target Screening gave us high confidence in our therapeutic target validation. Knowing that our gRNA was clean allowed us to proceed with preclinical studies without worrying about unintended edits."
Ms. Priya Singh, VP of Preclinical Development
"We commissioned CD Biosynsis to support an intricate gene editing project with multiple targets. Their talent in producing high-quality work in a short period of time was impressive. Their solutions were custom made to suit our needs, and they went above and beyond to ensure our experiments worked. Their support has been a great asset to our research department and we look forward to further working with them."
Dr. Raj Patel, Principal Investigator, Department of Molecular Biology
"As a pharmaceutical company working to discover new cancer therapies, we require accurate, trustworthy gene editing solutions. CD Biosynsis did more than what we expected when it came to providing strong, accurate CRISPR/Cas9 solutions for our preclinical research. Their technical support team was excellent and responsive, and they quickly replied to our questions. This alliance has been pivotal in helping us move our drug pipeline forward. Thank you, CD Biosynsis, for your amazing service!"
Dr. Clara Rodriguez, Chief Scientist, AstraZeneca Pharmaceuticals, Spain
What is the difference between a CRISPR Knockout and a Knock-in?
Knockout (KO): Uses the non-homologous end joining (NHEJ) pathway to create insertions/deletions (indels) that disrupt the gene's reading frame, effectively turning the gene off. Knock-in (KI): Uses the homology-directed repair (HDR) pathway to precisely insert a new DNA sequence (reporter, tag, or mutation) into a specific genomic location.
How do you confirm the success of a Knock-in experiment?
Success is confirmed through multiple steps: 1) Genotyping PCR/Sequencing across the insertion site to confirm the presence and correct sequence of the inserted DNA; 2) Functional Assays (Western Blot or Microscopy) to verify the expression of the new gene or tagged protein.
What is the complexity of your CRISPR Libraries?
Our CRISPR libraries typically contain multiple gRNAs per target gene and can achieve complexities suitable for screening the entire human genome (over 20,000 genes), ensuring comprehensive target coverage for functional studies.
Which organisms can you perform CRISPR gene editing in?
We provide CRISPR services across a wide range of model systems, including standard mammalian cell lines (HEK, CHO, iPSCs), various human primary cells, and common microbial/fungal systems (E. coli, Yeast).
How much does Metabolic Engineering services cost?
The cost of Metabolic Engineering services depends on the project scope, complexity of the target compound, the host organism chosen, and the required yield optimization. We provide customized quotes after a detailed discussion of your specific research objectives.
Do your engineered strains meet regulatory standards?
We adhere to high quality control standards in all strain construction and optimization processes. While we do not handle final regulatory approval, our detailed documentation and compliance with best laboratory practices ensure your engineered strains are prepared for necessary regulatory filings (e.g., GRAS, FDA).
What to look for when selecting the best gene editing service?
We provide various gene editing services such as CRISPR-sgRNA library generation, stable transformation cell line generation, gene knockout cell line generation, and gene point mutation cell line generation. Users are free to select the type of service that suits their research.
Does gene editing allow customisability?
Yes, we offer very customised gene editing solutions such as AAV vector capsid directed evolution, mRNA vector gene delivery, library creation, promoter evolution and screening, etc.
What is the process for keeping data private and confidential?
We adhere to the data privacy policy completely, and all customer data and experimental data are kept confidential.
CRISPR-Cas9 technology represents a transformative advancement in gene editing techniques. The main function of the system is to precisely cut DNA sequences by combining guide RNA (gRNA) with the Cas9 protein. This technology became a mainstream genome editing tool quickly after its 2012 introduction because of its efficient, simple and low-cost nature.
The CRISPR gene editing system with its Cas9 version stands as a vital instrument for current biological research. CRISPR technology enables gene knockout (KO) through permanent gene expression blockage achieved by sequence disruption. Various scientific domains including disease modeling and drug screening employ this technology to study gene functions. CRISPR KO technology demonstrates high efficiency and precision but requires confirmation and verification post-implementation because unsatisfactory editing may produce off-target effects or incomplete gene knockouts which impact experimental result reliability. For precise and efficient Gene Editing Services - CD Biosynsis, Biosynsis offers comprehensive solutions tailored to your research needs.
The CRISPR-Cas9 knockout cell line was developed using CRISPR/Cas9 gene editing to allow scientists to remove genes accurately for research on gene function and disease models and pharmaceutical discovery. Genetic research considers this technology essential due to its high efficiency together with simple operation and broad usability.
If your question is not addressed through these resources, you can fill out the online form below and we will answer your question as soon as possible.
|
There is no product in your cart. |
CD Biosynsis is a leading customer-focused biotechnology company dedicated to providing high-quality products, comprehensive service packages, and tailored solutions to support and facilitate the applications of synthetic biology in a wide range of areas.